ReviewCureus2026
Effects of Hyperbaric Oxygen Therapy on Myocardial Injury and Inflammatory Biomarkers: A Systematic Review With Qualitative Synthesis.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocardial injury is a major predictor of adverse cardiovascular outcomes and is driven by both ischemic and inflammatory mechanisms. Hyperbaric oxygen therapy (HBOT), which delivers 100% oxygen at supra-atmospheric pressure, has been proposed to enhance tissue oxygenation, attenuate ischemia-reperfusion injury, and modulate inflammatory responses. However, its clinical effects on myocardial injury and inflammatory biomarkers remain unclear. This systematic review qualitatively synthesizes clinical evidence evaluating the impact of HBOT on myocardial injury and inflammatory biomarkers in adult patients. A systematic search of PubMed, Web of Science, Scopus, and the Cochrane Library through May 2025 identified randomized controlled trials and observational studies reporting myocardial injury markers (cardiac troponin I, cardiac troponin T, creatine kinase-myocardial band, creatine phosphokinase (CPK)) or inflammatory/endothelial biomarkers (C-reactive protein, high-sensitivity CRP, interleukin-6, tumor necrosis factor-alpha, endothelin-1, nitric oxide, adhesion molecules, heat shock protein 70). A meta-analysis was not performed due to substantial heterogeneity and incomplete reporting of dispersion measures. Five clinical studies including 431 patients were eligible. In acute myocardial infarction, HBOT was associated with reduced CPK levels (up to 35% reduction, p=0.03) and improved left ventricular ejection fraction (p<0.05) in randomized studies. In perioperative cardiac surgery settings, HBOT preconditioning was associated with lower postoperative inflammatory and myocardial injury biomarkers (p<0.05). In patients with chronic coronary artery disease, HBOT was linked to reductions in high-sensitivity CRP and endothelin-1 and increased nitric oxide levels (p<0.05), although one multicenter trial reported a non-significant reduction in CPK. Overall, current evidence suggests that HBOT may exert cardioprotective and anti-inflammatory effects through improved oxygen delivery and modulation of inflammatory pathways. However, available studies remain limited and heterogeneous, and larger, well-designed prospective trials are required to establish clinical benefit.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.